Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Thursday the availability of Trientine Hydrochloride Capsules USP in 250 mg.
The US Food and Drug Administration (FDA) approved Trientine Hydrochloride Capsules USP in 250 mg are a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules. The product can be stored at room temperature (20°C to 25°C or 68°F to 77°F) throughout the product shelf life of 24 months.
Dr. Reddy's Trientine Hydrochloride Capsules USP in 250 mg are available in 100 count bottles.
For the most recent 12 months ended December 2019, the Syprine brand and generic products had US sales of approximately USD94.2m MAT, according to IMS Health. Syprine is a trademark of Alton Pharma.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval